Drug Profile
Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience
Alternative Names: Atorvastatin - Oxford Pharmascience; OXP 003; OXP 004; Safestat™ Atorvastatin; Safestat™ Simvastatin; Simvastatin - Oxford PharmascienceLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Oxford Pharmascience
- Class Amides; Cardiovascular therapies; Fluorobenzenes; Heptanoic acids; Naphthalenes; Pyrroles; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Cardiovascular disorders in United Kingdom (PO)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (PO)
- 09 Nov 2016 Development of a new colon-targeted formulation of atorvastatin for cardiovascular disorders is ongoing in United Kingdom